Stereotaxis, Inc. reported significant financial performance improvements in its latest 10-Q filing for the quarter ending June 30, 2025. The company achieved total revenue of $8.8 million for the three months ended June 30, 2025, a 95% increase from $4.5 million in the same period last year. For the first half of 2025, revenue reached $16.3 million, up 43% from $11.4 million in the first half of 2024. The growth was primarily driven by increased sales of both systems and disposable interventional devices, with system sales rising to $3.0 million from $0.2 million year-over-year, and disposable sales increasing to $5.8 million from $4.3 million.
Despite the revenue growth, Stereotaxis reported a net loss of $3.8 million for the second quarter of 2025, compared to a loss of $5.8 million in the same quarter of 2024. The company’s cumulative net losses reached approximately $571.4 million as of June 30, 2025. The increase in costs of revenue, which rose to $4.2 million from $1.2 million, contributed to the overall loss, with gross margins decreasing to 52% from 74% due to changes in product mix and acquisition-related accounting impacts.
Strategically, Stereotaxis completed the acquisition of Access Point Technologies EP, Inc. (APT) on July 31, 2024, which is expected to enhance its capabilities in developing and manufacturing diagnostic catheters for cardiac ablation procedures. The integration of APT is anticipated to bolster Stereotaxis' innovation efforts and expand its product offerings. The company has also made progress in regulatory approvals, with the GenesisX RMN System receiving CE Mark approval in Europe and the MAGiC Sweep™ catheter obtaining FDA clearance in July 2025.
Operationally, Stereotaxis has seen an increase in customer engagement, with hundreds of electrophysiologists treating over 150,000 patients using its robotic technology. The company reported a total of 86 million shares of common stock outstanding as of June 30, 2025, reflecting a slight increase from the previous year. However, cash and cash equivalents decreased to $7.0 million from $12.2 million at the end of 2024, indicating a need for ongoing capital management as the company continues to invest in product development and commercialization.
Looking ahead, Stereotaxis plans to focus on advancing the adoption of its robotic magnetic navigation systems and proprietary devices in markets where regulatory clearance has been received. The company expects to incur additional losses in 2025 as it continues its research and development activities and expands its sales and marketing initiatives. Stereotaxis will also monitor macroeconomic conditions that may impact its operations and is exploring financing alternatives to support its growth strategy.
About Stereotaxis, Inc.
Stereotaxis designs and markets robotic systems for minimally invasive interventional procedures, primarily in electrophysiology and cardiology. Its core products include magnetic navigation systems, integrated information solutions, and compatible disposable devices. The company enhances procedural precision, safety, and efficiency, enabling complex treatments with broader physician access. Operating globally, it leverages strategic partnerships, regulatory expertise, and innovative R&D to advance robotic medical technology.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.